CYB mtDNA mutations and expression status of genes in the PI3K/AKT/mTOR signaling pathway in patients with schizophrenia

MakaleAçık Erişim
  • SDG 3 · Sağlık ve Kaliteli Yaşam

Özet

Purpose: This study aimed to screen for cytochrome b (CYB) mitochondrial DNA (mtDNA) mutations and analyze the mRNA expressions of genes in the PI3K/AKT/mTOR signaling pathway in patients with schizophrenia. Materials and Methods: In this study, whole blood was obtained from 44 schizophrenic patients and 41 healthy individuals for DNA (patients) and RNA (patients and control) isolation. Samples for CYB mtDNA mutations were amplified by PCR and identified by Sanger DNA sequencing. RT-PCR and 2- increment increment Ct method was used for mRNA expression of PIK3CA, AKT1, and mTOR genes. Results: In schizophrenia patients, m.15326 A > G (43/44), m.15452 C > A (5/44), m.15078 A > G (3/44), m.14872 C > T (3/44) and m.14798 T > C (3/44) was the most common CYB mtDNA mutations. In silico analysis showed that some of the mutations were associated with the harmful, disease-causing or benign character. The mRNA expression of the PIK3CA, AKT1, and mTOR genes in schizophrenia patients was significantly higher than in healthy individuals. There was a significant moderate positive correlation between the PIK3CA and AKT1 genes. In addition, by ROC analysis, PIK3CA, AKT1 and mTOR genes were found to have good diagnostic power in the patient group. ROC analyzes showed that PIK3CA in particular has significant diagnostic value for schizophrenia patients with 80% sensitivity and 63.4% specificity. Conclusion: Both of CYB mtDNA mutations frequency and PIK3CA, AKT1 and mTOR mRNA expression were higher in schizophrenic patients compared to healthy individuals. We believe that studying these mechanisms in

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/bayburt/14522Resmi atıflarda kullanılan kalıcı adres
DOI
https://doi.org/10.17826/cumj.1186118Yayıncı resmi DOI adresi
İndeks kayıtları
Kaydın indeks veri tabanlarındaki sayfası (aktarımda alınan kayıt numarasıyla). Erişim, indeksin kendi koşullarına bağlıdır.
Atıflar
WoS
1
OpenAlex
1
TR Dizin
1
Her kaynağın kendi saydığı toplam atıf; aktarım ve zenginleştirme sırasında alındı.
Tam Kayıt
AlanDeğerDil
dc.contributor.authorDirican, Ebubekir
dc.contributor.authorUzunçakmak, Sevgi Karabulut
dc.contributor.authorÖzcan, Halil
dc.date.accessioned2026-10-29T19:15:58.739420774Z
dc.date.available2026-10-29T19:15:58.739420774Z
dc.date.issued2022
dc.description.abstractPurpose: This study aimed to screen for cytochrome b (CYB) mitochondrial DNA (mtDNA) mutations and analyze the mRNA expressions of genes in the PI3K/AKT/mTOR signaling pathway in patients with schizophrenia. Materials and Methods: In this study, whole blood was obtained from 44 schizophrenic patients and 41 healthy individuals for DNA (patients) and RNA (patients and control) isolation. Samples for CYB mtDNA mutations were amplified by PCR and identified by Sanger DNA sequencing. RT-PCR and 2- increment increment Ct method was used for mRNA expression of PIK3CA, AKT1, and mTOR genes. Results: In schizophrenia patients, m.15326 A > G (43/44), m.15452 C > A (5/44), m.15078 A > G (3/44), m.14872 C > T (3/44) and m.14798 T > C (3/44) was the most common CYB mtDNA mutations. In silico analysis showed that some of the mutations were associated with the harmful, disease-causing or benign character. The mRNA expression of the PIK3CA, AKT1, and mTOR genes in schizophrenia patients was significantly higher than in healthy individuals. There was a significant moderate positive correlation between the PIK3CA and AKT1 genes. In addition, by ROC analysis, PIK3CA, AKT1 and mTOR genes were found to have good diagnostic power in the patient group. ROC analyzes showed that PIK3CA in particular has significant diagnostic value for schizophrenia patients with 80% sensitivity and 63.4% specificity. Conclusion: Both of CYB mtDNA mutations frequency and PIK3CA, AKT1 and mTOR mRNA expression were higher in schizophrenic patients compared to healthy individuals. We believe that studying these mechanisms in
dc.identifier.doi10.17826/cumj.1186118
dc.identifier.eissn2602-3040
dc.identifier.endpage1708
dc.identifier.issn2602-3032
dc.identifier.issue4
dc.identifier.startpage1695
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/bayburt/14522
dc.identifier.volume47
dc.identifier.wosWOS:000910852700037
dc.language.isotr
dc.publisherCUKUROVA UNIV, FAC MEDICINE
dc.relation.ispartofCUKUROVA MEDICAL JOURNAL
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectGenel ve Dahili Tıp
dc.subjectKlinik Nöroloji
dc.subjectNörolojik Bilimler
dc.subjectSağlık Bilimleri ve Hizmetleri
dc.subjectBiyokimya ve Moleküler Biyoloji
dc.subjectHücre Biyolojisi
dc.subjectPsikiyatri
dc.subject.classificationMedicine, General & Internal
dc.subject.classificationGeneral & Internal Medicine
dc.subject.otherCELL
dc.subject.otherAPOPTOSIS
dc.subject.otherDNA
dc.titleCYB mtDNA mutations and expression status of genes in the PI3K/AKT/mTOR signaling pathway in patients with schizophrenia
dc.typeArticle
rdl.citation.openalex1
rdl.citation.trdizin1
rdl.citation.wos1
rdl.oa.statusgold
rdl.oa.urlhttps://doi.org/10.17826/cumj.1186118
rdl.sdgSDG03
rdl.source.indexWOS
rdl.source.indexTRDIZIN
rdl.wos.indexEmerging Sources Citation Index (ESCI)